Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Announces Six Abstracts Accepted for Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting May 16, 2018 Nektar Therapeutics Reports Financial Results for the First Quarter of 2018 May 10, 2018 Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus May 08, 2018 Nektar to Announce Financial Results for the First Quarter 2018 on Thursday, May 10, 2018, After Close of U.S.-Based Financial Markets May 03, 2018 Nektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual Meeting Apr 30, 2018 New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors Apr 24, 2018 Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018 Apr 15, 2018 Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors Apr 11, 2018 Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb Apr 03, 2018 Nektar to Webcast Presentation at the Cowen and Company 38th Annual Health Care Conference in Boston Mar 07, 2018 Pagination First page « first Previous page ‹ previous … Page 12 Page 13 Page 14 Page 15 Current page 16 Page 17 Page 18 Page 19 Page 20 … Next page next › Last page last »